ClinicalTrials.gov
public full text
Public Domain
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
2QG1 is a Phase IIa study aiming to assess the blood pressure lowering effect of 4-week administration of QGC001 oral doses in patients with grade I or II essential hypertension compared to placebo, to assess the safety and tolerability, to obtain preliminary PK information for QGC001 given as multiple oral doses and to determine preliminary PD profile of QGC001 multiple oral doses on plasma and urine hormones, which will be compared to that of placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer#835758
- Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension#840619
- Guidelines for Drug Therapy of Hypertension: Closing the Loop#125998
- Amlodipine Diabetic Hypertension Efficacy Response Trial#887330
- Multi-Omics to Predict the Blood Pressure Response to Antihypertensives#967106
Record · ID 993696
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive